NCT04892017 2026-04-08Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsDeciphera Pharmaceuticals, LLCPhase 1 Terminated91 enrolled
NCT04585815 2026-01-09Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)PfizerPhase 1/2 Terminated34 enrolled 44 charts
NCT04913285 2025-12-24A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsPierre Fabre MedicamentPhase 1 Active not recruiting400 enrolled
NCT01763164 2021-03-22Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaPfizerPhase 3 Completed402 enrolled 21 charts